As it prepares for its 30th Birthday party this June, Eden Research (EDEN) must also be preparing for what it does best: another deeply discounted placing and with the fragrant Jo Hart at Midas no longer pumping the worthless shares with fanciful predictions this could be messy. No placing and a material uncertainty warning is a nailed on cert.
There were Frank and Britain’s Buffet, Mark, itching to buy shares in Eurasia Mining (EUA) as they raced ahead to almost 8p just a few days ago, I urged them to resist the temptation. So what if a company with sub economic assets, a track record of lying, no cash and a death spiral in play was capitalized at £200 million +, the shares are going up and up and the Telegram groups say they are going higher. After the pump…
Yesterday, with assistance from Evil Banksta I exposed HERE and HERE, just how pungent is the latest acquisition and bailout of Argo Blockchain (ARB). It stinks to high heaven and the FCA should be all over it. It is the first deal announced by Argo’s new CEO Justin Nolan. But what of his last masterstroke at Argo on his first tour of duty there.
On 21 March 2025 Wellnex (WNX) announced its admission to trading on AIM having raised £5.22 million at 31.75p capitalising this already ASX listed company at £21 million. The day before it paid brown envelope man Zak Mir to do a fawning interview masquerading as journalism, a sure sign that you should avoid the shares, now 26.5p, like the plague.
It is once again ouzo on cornflakes time at the Sheriff of AIM Towers for a battle that started two years ago when Celadon (CEL) shares were 125p us now all over bar the shouting. It’s time for one PR supremo to congratulate me on two years of most excellent journalism. The shares are now 11p but will fall steadily as folks wake up to the horror that awaits.
Oh dear, oh dear as disgraced ex tipster Mike Walters used to say as yet another of his share tips went disastrously wrong. And Celadon Pharmaceuticals (CEL) is exactly the sort of POS that Mike would love to have tipped. It announces contracts with a vast top line number but the sales never arrive, profits are a pipe dream and as for cash being generated, forget it. The management are obvious knaves who do not give a FF about listing disclosure rules and the financing of the enterprise is, to say the least, opaque.
It is not quite up there with Eden Research (EDEN) and Blackbird (BIRD) in the AIM listed jam tomorrow contest. They were both founded in the last Century. But Sareum (SAR) will turn 21 this June and has never made a profit. So far in its miserable life it has sent more than £25 million to money heaven and at 14.75p after another keep the lights on placing it is capitalised at c £18 million. So sticking that £25 million in a building society account would have been a far better investment.